Instant Feedback
Listen Here. K-Heart 106.9 FM - Contemporary Christian
Listen Here. KHRT 1320 AM - Southern Gospel
E-Mail Sign Up
The Latest

Wed., 1/23/19

- First Baptist Church of Minot has cancelled all services and activities tonight




God's will is what we would choose if we knew what God knows.

- Nancy Leigh DeMoss

Verse of the Day

Bible Reading



North Dakota's Health Department has selected two finalists to be potential manufacturers of medical marijuana....

     BISMARCK, N.D. (AP) - North Dakota's Health Department has selected two finalists to be potential manufacturers of medical marijuana. Medical Marijuana Division Director Jason Wahl on Wednesday announced the finalists from a field of 19 applicants. Wahl says Pure Dakota would locate their facility in Bismarck and Grassroots Cannabis would have their factory in Fargo. Wahl says the two manufacturing facilities still must adhere to additional requirements before getting final approval.
     A seven-member panel made up of health officials, citizens, law enforcement and a state lawyer scored the applications. Applicants had to submit a $5,000 nonrefundable fee.
     State officials have been developing the medical marijuana system since legislators crafted a law a year ago. That followed voters' approval of the drug for medical purposes in November 2016.


     BISMARCK, N.D. (AP) - North Dakota natural gas production hit another record in March even as oil production dropped, illustrating the need for more gas infrastructure.

    The Mineral Resources Department reports the state produced more than 2.1 billion cubic feet per day of natural gas, with companies flaring about 12 percent. Flaring is considered wasteful, and the state restricts it.

    North Dakota Pipeline Authority Director Justin Kringstad tells The Bismarck Tribune that gas production is expected to exceed processing capacity beginning this summer until projects under construction start to come online.

    The Public Service Commission granted approval Tuesday for Oneok to proceed with the Demicks Lake natural gas processing plant in McKenzie County. It's one of five such plants under development in North Dakota. It's expected to be complete late next year.


     BILLINGS, Mont. (AP) - Federal officials are being asked to investigate whether a financially-troubled coal company has posted sufficient bonds to cover future reclamation work at its mines in the U.S. and Canada.

    The Montana-based Western Organization of Resource Councils said Wednesday that it's concerned a bankruptcy by Westmoreland Coal could leave taxpayers to cover future reclamation costs. It asked the Interior Department to investigate.

    The Englewood, Colorado company told The Associated Press in a statement that it's in full compliance with mining regulations.

    Westmoreland disclosed last month to securities regulators that it's considering filing for bankruptcy protection. It reported posting $673 million in reclamation bonds and letters of credit.

    Westmoreland sold 50 million tons of coal last year from its mines in Montana, Wyoming, New Mexico, Texas, North Dakota, Ohio, Alberta and Saskatchewan.


     TRENTON, N.J. (AP) - Federal regulators have approved the first nonopioid treatment to ease withdrawal symptoms from quitting addictive opioids. The U.S. Food and Drug Administration expedited approval of Lucemyra to help combat the U.S. opioid epidemic.
     The tablet was approved Wednesday to treat adults for up to two weeks for common withdrawal symptoms like vomiting, diarrhea, muscle pain and agitation. It is not an addiction treatment but can be part of a longer-term plan.
     People going through detox are usually given opioid medicine like methadone, which eases the cravings without an intense high. Fear of withdrawal discourages some people from quitting.
     The FDA is requiring drugmaker US WorldMeds of Louisville, Kentucky, to conduct safety studies in teens and newborns of opioid-addicted mothers and for possible longer-term use in people tapering off opioids.


     UNDATED (AP) - New research suggests that many women with a common and aggressive form of breast cancer that is treated with Herceptin can get by with six months of the drug instead of the usual 12. That greatly reduces the risk of heart damage the drug can cause.
     About 20 percent of breast cancers are aided by a faulty HER2 gene, which Herceptin targets. Concern about heart side effects led doctors in the United Kingdom to test shorter use.
     About 4,000 women with early-stage cancers were given chemotherapy plus Herceptin for six or 12 months. After four years, 90 percent of both groups were alive without signs of the disease.
     Results were released Wednesday by the American Society of Clinical Oncology ahead of presentation at its meeting next month.





   (Copyright 2018 by The Associated Press.  All Rights Reserved.)


Visitor Comments (0)

Be the first to post a comment.
© 2012 - 2019 KHRT Radio - All Rights Reserved.